Bibliography
- WILD SH, BYRNE CD: The global burden of the metabolic syndrome and its consequences for diabetes and cardiovascular disease. In: Metabolic syndrome. Byrne CD, Wild S (Eds), Wiley & Sons Ltd, UK (2005):1-32.
- HALL JE: The kidney, hypertension, and obesity. Hypertension (2003) 41:625-633.
- WESSON DE, KURTZMAN NA, FROMMER JP: Massive obesity and nephrotic proteinuria with a normal renal biopsy. Nephron (1985) 40:235-237.
- KAMBHAM N, MARKOWITZ GS, VALERI AM, LIN J, D’AGATI VD: Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. (2001) 59:1498-1509.
- GADES MD, VAN GOOR H, KAYSEN GA, JOHNSON PR, HORWITZ BA, STERN JS: Brief periods of hyperphagia cause renal injury in the obese Zucker rat. Kidney Int. (1999) 56:1779-1787.
- CHAGNAC A, WEINSTEIN T, HERMAN M, HIRSH J, GAFTER U, ORI Y: The effects of weight loss on renal function in patients with severe obesity. J. Am. Soc. Nephrol. (2003) 14:1480-1486.
- VAN GAAL LF, RISSANEN AM, SCHEEN AJ, ZIEGLER O, ROSSNER S; RIO-EUROPE STUDY GROUP: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet (2005) 365(9468):1389-1397.
- DESPRES JP, GOLAY A, SJOSTROM L; RIMONABANT IN OBESITY-LIPIDS STUDY GROUP: Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. (2005) 353(20):2121-2134.